AnaSpec Introduces new OVA GO™ Peptides
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Continuing to expand its collection of ready-to-go peptides, AnaSpec has released a new selection of OVA peptides in the GO™ peptide format.
Proteolytic processing of proteins in the cytoplasm generates peptide epitopes that are generally 8-10 amino acids in length. The binding of these peptides to the surface major histocompatibility complex (MHC) class I molecules and subsequent presentation to T-cells elicits an immune response. A model antigen extensively studied is Ovalbumin (OVA). OVA is processed to the presenting octapeptide (257-264), SIINFEKL, through proteasomal and non-proteasomal activities. As with peptides naturally presented by H-2Kb, SIINFEKL has on its 5th position an amino acid with an aromatic side chain (Phe) and on the 8th position, an aliphatic side chain (Leu).3 Variants of this peptide consisting of substituting different amino acids at strategic positions have yielded valuable information on the interaction of this peptide and the MHC complex.
The use of AnaSpec’s SIINFEKL has been reported in peer-reviewed journals since 1997. We are pleased that researchers have trusted us to provide this important peptide. We are also pleased to announce the recent release of variants of this peptide.
Proteolytic processing of proteins in the cytoplasm generates peptide epitopes that are generally 8-10 amino acids in length. The binding of these peptides to the surface major histocompatibility complex (MHC) class I molecules and subsequent presentation to T-cells elicits an immune response. A model antigen extensively studied is Ovalbumin (OVA). OVA is processed to the presenting octapeptide (257-264), SIINFEKL, through proteasomal and non-proteasomal activities. As with peptides naturally presented by H-2Kb, SIINFEKL has on its 5th position an amino acid with an aromatic side chain (Phe) and on the 8th position, an aliphatic side chain (Leu).3 Variants of this peptide consisting of substituting different amino acids at strategic positions have yielded valuable information on the interaction of this peptide and the MHC complex.
The use of AnaSpec’s SIINFEKL has been reported in peer-reviewed journals since 1997. We are pleased that researchers have trusted us to provide this important peptide. We are also pleased to announce the recent release of variants of this peptide.
